Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

References

• Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56:226–243.
   PubMed Web of Science ®Google Scholar
• Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008;36:755–768.
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, et al Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868–2878.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphoma. Blood 2004;104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Beyer J, Howell K, et al Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 2005;28:212–219.
   PubMed Web of Science ®Google Scholar
• Umana P, Moessner E, Grau R, et al GA101, a novel therapeutic type II CD20 antibody with outstanding anti-tumor efficacy in non-Hodgkin lymphoma xenograft models and superior B cell depletion. Ann Oncol 2008;19(Suppl. 7): Abstract 98.
   Google Scholar
• Martin P, Furman RR, Ruan J, et al Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol 2008;45:126–132.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823–3837.
   PubMed Web of Science ®Google Scholar
• Maloney DG. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am Soc Hematol Educ Program 2007:226–232.
   PubMedGoogle Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450–454.
   PubMedGoogle Scholar
• Press OW, Appelbaum F, Ledbetter JA, et al Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584–591.
   PubMed Web of Science ®Google Scholar
• Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390–1397.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 2006;6:1341–1353.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113:1062–1070.
   PubMed Web of Science ®Google Scholar
• Tahir H, Rohrer J, Bhatia A, et al Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 2005;44:561–562.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Fayad L, et al Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009;27:3346–3353.
   PubMed Web of Science ®Google Scholar
• Saleh MN, Liebman H, Bernstein ZP, et al Subcutaneous injections of low-dose anti-CD20 veltuzumab for treatment of relapsed immune thrombocytopenia (ITP). Blood 2009;114(Suppl. 1): 541 (Abstract 1322).
   Google Scholar
• Cheson BD, Horning S, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, et al Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135–3143.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Genentech: Rituxan (Rituximab) full prescribing information. Available from: http://www.gene.com/gene/products/information/oncology/rituxan/insert.jsp.
   Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, et al Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711–4716.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briére J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Kobayashi Y, Ogura M, et al Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002;13:928–943.
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZS, Cunningham D, et al European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317–324.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, et al Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047–2055.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, et al Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995–1001.
   PubMed Web of Science ®Google Scholar
• Gordon LN, Grow WB, Pusateri A, et al Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096–1102.
   PubMed Web of Science ®Google Scholar
• Cartron G, Blasco H, Paintaud G, et al Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007;62:43–52.
   PubMed Web of Science ®Google Scholar
• Negrea OG, Allen SL, Rai KR, et al Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malignancies. Blood 2009;114(Suppl. 1): 1446 (Abstract 3757).
   Google Scholar
• Forstpointner R, Dreyling M, Repp R, et al The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–3071.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Decaudin D, Mounier N, et al 90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA Phase II study. Blood 2007;110(Suppl. 1):14a (Abstract 22).
   Google Scholar
• Sharkey RM, Brenner A, Burton J, et al Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003;44:2000–2018.
   PubMed Web of Science ®Google Scholar
• Lindén O, Hindorf C, Cavallin-Ståhl E, et al Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005;11:5215–5222.
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F, Morschhause F, Huglo D, et al Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: results at high cumulative doses of 90Y. J Clin Oncol 2008;26(Suppl.): 454s (Abstract 8502).
   Google Scholar
• Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 2008;14:6154–6160.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas J, et al Combination antibody therapy with e-mab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044–5051.
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Morschhauser F, Rech J, et al Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, e-mab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006;24:3880–3886.
   PubMed Web of Science ®Google Scholar
• Leonard, JP, Schuster SJ, Emmanouilides C, et al Durable complete responses from therapy with combined e-mab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113:2714–2723.
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang C-H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 2006;103:6841–6846.
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009;113:6161–6171.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Giovarelli M, Modesti A, et al IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994;153:4604–4615.
   PubMed Web of Science ®Google Scholar
• Gresser I, Coppey J, Bourali C. [Inhibiting action of crude interferon on lymphoid leukemia in AKR mice]. CR Acad Sci Hebd Seances Acad Sci D 1968;267:1900–1902.
   PubMed Web of Science ®Google Scholar
• Gresser I, Maury C, Brouty-Boye D. Mechanism of the antitumour effect of interferon in mice. Nature 1972;239:167–168.
   PubMed Web of Science ®Google Scholar
• Gutterman JU, Blumenschein GR, Alexanian R, et al Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980;93:399–406.
   PubMed Web of Science ®Google Scholar
• Kimby E, Jurlander J, Geisler C, et al Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008;49:102–112.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, et al Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824–4831.
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009;114:3864–3871.
   Google Scholar